设为首页 加入收藏

TOP

Aclasta 5 mg solution for infusion Zoledronic Acid
2014-02-16 23:05:26 来源: 作者: 【 】 浏览:417次 评论:0

For doctors

 

What is it and how is it used?

Aclasta contains the active substance zoledronic acid. It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and men with osteoporosis or osteoporosis caused by treatment with steroids, and Paget’s disease of the bone.

Osteoporosis
Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men. At the menopause, a woman’s ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. Following the menopause bone loss occurs, bones become weaker and break more easily. Osteoporosis could also occur in men and women because of the long term use of steroids, which can affect the strength of bones. Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker. Decreased circulating levels of sex hormones, mainly oestrogens converted from androgens, also play a role in the more gradual bone loss observed in men. In both women and men, Aclasta strengthens the bone and therefore makes it less likely to break. Aclasta is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.

Paget’s disease of the bone
It is normal that old bone is removed and is replaced with new bone material. This process is called remodelling. In Paget’s disease, bone remodelling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal. If the disease is not treated, bones may become deformed and painful, and may break. Aclasta works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.

What do you have to consider before using it?

Follow all instructions given to you by your doctor carefully before you are given Aclasta.

You should not be given Aclasta

Take special care with Aclasta
Tell your doctor before you are given Aclasta:

Before you receive treatment with Aclasta, tell your doctor if you have (or have had) pain, swelling or numbness in your gums, jaw or both, if your jaw feels heavy, or if you have lost a tooth. Before you receive dental treatment or undergo dental surgery, tell your dentist you are receiving treatment with Aclasta.

Use in children
Aclasta is not recommended for anyone under 18 years of age. The use of Aclasta in children and adolescents has not been studied.

Taking other medicines
Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

It is especially important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration.

Using Aclasta with food and drink
Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with Aclasta, as directed by your doctor. This will help to prevent dehydration. You may eat normally on the day you are treated with Aclasta. This is especially important in patients who take diuretics (“water pills”) and in elderly patients.

Pregnancy and breast-feeding
There is no adequate information on the use of zoledronic acid in pregnant women. Studies in animals have shown reproductive toxicological effects. Additionally, there is no information on the use of Aclasta in breast-feeding women. You must not be given Aclasta if you are pregnant or plan to become pregnant.

You must not be given Aclasta if you are breast-feeding.

Ask your doctor, pharmacist or nurse for advice before taking any medicine.

Driving and using machines
If you feel dizzy while taking Aclasta, do not drive or use machines until you feel better.

How is it used?

Follow carefully all instructions given to you by your doctor or nurse. You should check with your doctor or nurse if you are not sure.

Your doctor should do a blood test to check your kidney functions (levels of creatinine) before each dose of Aclasta. It is important for you to drink at least one or two glasses of fluid (such as water), within a few hours before receiving Aclasta, as directed by your doctor or nurse.

Osteoporosis
The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse. The infusion will take at least 15 minutes.

In case you recently broke your hip, it is recommended that Aclasta is administered two or more weeks after your hip repair surgery.

It is important to take calcium and vitamin D supplements (for example tablets) as directed by your doctor.

For osteoporosis, Aclasta works for one year. Your doctor will let you know when to return for your next dose.

Paget’s disease
The usual dose is 5 mg, given to you as one single infusion into a vein by your doctor or nurse. The infusion will take at least 15 minutes. Aclasta may work for longer than one year, and your doctor will let you know if you need to be treated again.

Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Aclasta. It is important that you follow this advice carefully so that the level of calcium in your blood does not become too low in the period after the infusion. Your doctor will inform you regarding the symptoms associated with hypocalcaemia.

If a dose of Aclasta is missed
Contact your doctor or hospital as soon as possible to re-schedule your appointment.

Before stopping Aclasta therapy
If you are considering stopping Aclasta treatment, please go to your next appointment and discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with Aclasta.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

What are possible side effects?

Like all medicines, Aclasta can cause side effects, although not everybody gets them. In most cases, no specific treatment is required.

Side effects may occur with certain frequencies, which are defined as follows:

Very common affects more than 1 user in 10 Common affects 1 to 10 users in 100 Uncommon affects 1 to 10 users in 1,000 Rare affects 1 to 10 users in 10,000 Very rare affects less than 1 user in 10,000 Not known frequency cannot be estimated from the available data.

Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions. The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Aclasta. The symptoms are usually mild to moderate and go away within three days. Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects. The chance of experiencing these side effects decreases with subsequent doses of Aclasta.

Very common side effects

Fever

Common side effects
Headache, dizziness, sickness, vomiting, diarrhoea, pain in the muscles, pain in the bones and/or joints, pain in the back, arms or legs, flu-like symptoms (e.g. tiredness, chills, joint and muscle pain), chills, feeling of tiredness and lack of interest, weakness, pain, feeling unwell, skin reactions such as redness, swelling and/or pain at the infusion site.

In patients with Paget’s disease: symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth.

Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving Aclasta for post-menopausal osteoporosis. It is currently unclear whether Aclasta causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Aclasta.

Uncommon side effects
Flu, upper respiratory tract infections, decreased red cell count, loss of appetite, sleeplessness, sleepiness which may include reduced alertness and awareness, tingling sensation or numbness, extreme tiredness, trembling, temporary loss of consciousness, eye infection or irritation or inflammation with pain and redness, eye sensitivity to light, spinning sensation, increased blood pressure, flushing, cough, shortness of breath, upset stomach, abdominal pain, constipation, dry mouth, heartburn, skin rash, excessive sweating, itching, skin reddening, neck pain, stiffness in muscles, bones and/or joints, joint swelling, muscle spasms, shoulder pain, pain in your chest muscles and rib cage, joint inflammation, muscular weakness, abnormal kidney test results, abnormal frequent urination, swelling of hands, ankles or feet, thirst, toothache, taste disturbances.

Additional side effects which have been reported (frequency not known): severe allergic reactions including dizziness and difficulty breathing, swelling mainly of the face and throat, decreased blood pressure, pain in the mouth, teeth and jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth, kidney disorder (e.g. decreased urine output), dehydration secondary to post-dose symptoms such as fever, vomiting and diarrhoea.

If you notice any of these side effects, tell your doctor.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, pharmacist or nurse.

How should it be stored?

Your doctor, pharmacist or nurse knows how to store Aclasta properly.

↑ back to table of contents ↑

For doctors

What is it?

Aclasta is a solution for infusion (drip into a vein) that contains the active substance zoledronic acid.

What is it used for?

Aclasta is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men. It is used in patients who are at risk of fractures (broken bones) including those who have recently broken their hip in a minor trauma such as a fall, and in patients whose osteoporosis is linked to long-term treatment with glucocorticoids (a type of steroid).

Aclasta is also used to treat Paget’s disease of the bone in adults. This is a disease where the normal process of bone growth is changed.

The medicine can only be obtained with a prescription.

How is it used?

Aclasta is given as an infusion lasting at least 15 minutes. This can be repeated once a year in patients being treated for osteoporosis. Patients who have broken their hip should receive Aclasta at least two weeks after the operation to repair the fracture. For Paget’s disease, only one infusion of Aclasta is usually given, but additional infusions can be considered if the patient’s disease comes back. The effect of each infusion lasts for a year or more.

Patients must have adequate fluids before and after treatment, and should receive adequate supplements of vitamin D and calcium. Using paracetamol or ibuprofen (anti-inflammatory medicines) shortly after Aclasta can reduce symptoms such as fever, muscle pain, influenza (flu)-like symptoms, joint pain and headache in the three days following the infusion. In the treatment of Paget’s disease of the bone, Aclasta must only be used by a doctor who has experience in the treatment of the disease. Aclasta should not be used in patients with severe kidney problems. See the Package Leaflet for full details.

How does it work?

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to fracture. In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall. Osteoporosis can also occur in both sexes as a side effect of glucocorticoid treatment. In Paget’s disease, the bone breaks down more quickly, and when it grows back, it is weaker than normal.

The active substance in Aclasta, zoledronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease. Zoledronic acid has also been authorised in the European Union (EU) as Zometa since March 2001 for the prevention of bone complications in patients with cancer that is affecting the bone, and for the treatment of hypercalcaemia (high blood calcium levels) caused by tumours.

How has it been studied?

Because zoledronic acid has been authorised in the EU as Zometa for a number of years, the company presented the results of some studies carried out with Zometa, which were taken into account when assessing Aclasta.

For osteoporosis, Aclasta has been studied in three main studies. The first compared Aclasta with placebo (a dummy treatment) in almost 8,000 elderly women with osteoporosis, looking at the number of fractures in the spine and the hip over three years. The second study compared Aclasta with placebo in 2,127 men and women with osteoporosis who had recently broken their hip, and looked at the number of fractures over up to five years. The third compared one infusion of Aclasta with daily treatment with risedronate (another bisphosphonate) in 833 men and women with osteoporosis caused by glucocorticoids, and looked at the change in the density of the bones in the spine over a year. In these studies, the patients could take other medicines for osteoporosis, but not other bisphosphonates.

For Paget’s disease, Aclasta has been compared with risedronate in a total of 357 adults in two studies lasting six months. The patients received one infusion of Aclasta or they took risedronate once a day for two months. The main measure of effectiveness was the number of patients who responded to treatment, defined as blood levels of serum alkaline phosphatase (an enzyme involved in the breakdown of bone) returning to normal or falling at least three-quarters of the way back to normal.

What benefits has it shown during the studies?

In osteoporosis, Aclasta was more effective than the comparator medicines. In the study of elderly women, the risk of fractures in the spine was reduced by 70% in patients taking Aclasta (without any other medicines for osteoporosis) over three years when compared with those taking placebo. There was a 41% risk reduction in hip fractures, when comparing all women taking Aclasta (with or without other osteoporosis medicines) with those taking placebo. In the study of men and women who had broken their hip, 9% of the patients receiving Aclasta had a fracture (92 out of 1,065), compared with

13% of the patients receiving placebo (139 out of 1,062). Finally, Aclasta was more effective than risedronate at increasing spine bone density over a year’s treatment in patients taking glucocorticoids.

In Paget’s disease, Aclasta was more effective than risedronate. After six months, around 96% of patients had responded to treatment in the two studies, compared with around 74% of the patients who received risedronate.

What is the risk associated?

Most side effects with Aclasta tend to occur within the first three days after infusion, becoming less common with repeated infusions. The most common side effect with Aclasta (seen in more than 1 patient in 10) is fever. For the full list of all side effects reported with Aclasta, see the Package Leaflet.

Aclasta should not be used in people who may be hypersensitive (allergic) to zoledronic acid, to other bisphosphonates or to any of the other ingredients. Aclasta must not be used in patients with hypocalcaemia (low blood calcium levels), or in pregnant or breast-feeding women.

Why has it been approved?

The CHMP decided that Aclasta’s benefits are greater than its risks and recommended that it be given marketing authorisation.

How has it been studied?

The company that makes Aclasta will provide educational packs in each Member State for doctors who prescribe Aclasta for osteoporosis, reminding them how the medicine should be used, and similar packs for patients to explain the medicine’s side effects and when patients should contact their doctor.

Further information

The European Commission granted a marketing authorisation valid throughout the EU for Aclasta to Novartis Europharm Limited on 15 April 2005. After five years, the marketing authorisation was renewed for a further five years.

For more information about treatment with Aclasta, read the Package Leaflet (also part of the EPAR).

This summary was last updated in 04-2010.

↑ back to table of contents ↑
 

Name

 

Aclasta 5 mg solution for infusion

 

Composition

 

Each bottle with 100 ml of solution contains 5 mg zoledronic acid (as monohydrate).

Each ml of the solution contains 0.05 mg zoledronic acid anhydrous, corresponding to 0.0533 mg zoledronic acid monohydrate.

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Solution for infusion

Clear and colourless solution.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇ACLASTA 5 mg solution for infus.. 下一篇Aclasta (zoledronic acid)

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位